EXECUTIVE FUNCTIONS IN YOUNG ADULTS AGED 19 TO 24 YEARS WITH BREAST CANCER: AN EXPLORATORY REVIEW OF THE LITERATURE BETWEEN 2015 AND 2020 / FUNCIONES EJECUTIVAS EN ADULTOS JÓVENES DE 19 A 24 AÑOS CON CÁNCER DE MAMA: REVISIÓN EXPLORATORIA DE LITERATURA ENTRE 2015 Y 2020

With the growth and aging of the population, along with economic growth and changes in lifestyles associated with increased quality of life, the main burden of disease shifted from infectious diseases to noncommunicable and complex diseases. However, it is cancer that has increased its incidence in the world population, especially in low- and middle-income countries, where 70% of cancer deaths occur.  The research is articulated to sustainable development goal three, in particular on the effect of cancer on cognitive functioning, because cancer pain impairs cognitive functioning. A simple review for executive functions and breast cancer in PROSPERO indicated an absence of reviews on this topic. Reason why, our aim is to describe executive functions and treatment effect by chemotherapy/radiotherapy in young adult breast cancer patients between 2015 and 2020 in the scientific literature. Materials and methods: exploratory literature review according to PRISMA protocol for exploratory reviews. Articles published in Scopus, PubMed, ScienceDirect, scielo, google academic, in Spanish, English, French. With the keywords: ("Executive Function") AND ("Neoplasms") OR "breast cancer" OR "Drug Therapy," AND ("Young Adult"), searches were performed until February 4, 2020. Results: 16 articles included in the review. Clinical and methodological heterogeneity was found on patients' executive functions and treatment. However, we did find executive function impairment among patients assessed by both treatment and cancer. Conclusions: A systematic review on the subject and meta-analysis are suggested to identify the effect size, accompanied by the statistical evidence identified in the studies. Colombia could investigate this topic because there is no Colombian research.

Con el crecimiento y envejecimiento de la población, junto al crecimiento económico y los cambios en los estilos de vida asociados al incremento en la calidad de vida, la principal carga de morbilidad pasó de las enfermedades infecciosas a las no transmisibles y complejas. Sin embargo, es el cáncer incrementó su incidencia en la población mundial, especialmente en países de ingresos bajos y medios, dónde el 70% de las muertes por cáncer se presentan.  La investigación se articula al objetivo de desarrollo sostenible tres, en particular sobre el efecto del cáncer sobre el funcionamiento cognitivo, debido a que el dolor por cáncer deteriora el funcionamiento cognitivo. Una revisión sencilla por funciones ejecutivas y cáncer de mama en PROSPERO indicó una ausencia de revisiones en este tema. Razón por la cual, nuestro objetivo es describir las funciones ejecutivas y el efecto del tratamiento por quimioterapia/radioterapia en pacientes con cáncer de mama en adultos jóvenes entre 2015 y 2020 en la literatura científica. Materiales y métodos: Revisión exploratoria de literatura según protocolo PRISMA para revisiones exploratorias. Artículos publicados en Scopus, PubMed, ScienceDirect, scielo, google académico, en idioma español, inglés, francés. Con las palabras clave: ("Executive Function") AND ("Neoplasms") OR "breast cancer" OR "Drug Therapy," AND ("Young Adult"), las búsquedas se realizaron hasta el 4 de febrero de 2020. Resultados: 16 artículos incluidos en la revisión. Se encontró heterogeneidad clínica y metodológica sobre las funciones ejecutivas de los pacientes y el tratamiento. Sin embargo, sí se encontró afectación de funciones ejecutivas entre los pacientes evaluados tanto por el tratamiento cómo por el cáncer. Conclusiones: Se sugiere una revisión sistemática sobre el tema y meta-análisis para identificar el tamaño del efecto, acompañado de la evidencia estadística identificada en los estudios. Colombia podría investigar sobre esta temática debido a que no hay investigaciones colombianas.

Com o crescimento e o envelhecimento da população, juntamente com o desenvolvimento económico e as mudanças nos estilos de vida associadas ao aumento da qualidade de vida, o principal fardo da doença mudou de doenças infecciosas para doenças não transmissíveis e complexas. No entanto, é o câncer que aumentou a sua incidência na população mundial, especialmente nos países de baixa e média renda, onde 70% das mortes por câncer ocorrem. A pesquisa está articulada com o Objectivo de Desenvolvimento Sustentável 3, em particular sobre o efeito do câncer sobre o funcionamento cognitivo, porque a dor do cancro prejudica a função cognitiva. Uma simples revisão para funções executivas e câncer de mama em PROSPERO indicou uma ausência de comentários sobre este tópico. A razão pela qual, nosso objetivo é descrever as funções executivas e o efeito do tratamento por quimioterapia/radioterapia em pacientes jovens adultos com câncer de mama entre 2015 e 2020 na literatura científica. Materiais e métodos: revisão da literatura exploratória de acordo com o protocolo PRISMA para revisões exploratórias. Artigos publicados em Scopus, PubMed, ScienceDirect, scielo, google academic, em espanhol, inglês, francês. Com as palavras-chave: ("Função Executiva") E ("Neoplasmas") OU "câncer de mama" OU" Terapia de drogas," E ("Jovem Adulto"), as pesquisas foram realizadas até 4 de fevereiro de 2020. Resultados: 16 artigos incluídos na revisão. Foi encontrada heterogeneidade clínica e metodológica nas funções executivas e no tratamento dos pacientes. No entanto, descobrimos que a função executiva foi prejudicada entre os pacientes avaliados tanto pelo tratamento como pelo câncer. Conclusões: Sugere-se uma revisão sistemática do assunto e meta-análise para identificar o tamanho do efeito, acompanhada das provas estatísticas identificadas nos estudos. A Colômbia poderia investigar este assunto porque não há pesquisa colombiana.

Déficit de atención con hiperactividad: farmacoterapia a través de la vida / Attention deficit hyperactivity: pharmacotherapy through life

Resumen El Trastorno por déficit de atención con hiperactivi dad (TDAH) es un trastorno del neurodesarrollo de ori gen biológico con una base genética del 70 al 80%, que afecta al 5% de niños y adolescentes y a un 2.5% de los adultos, cuyos síntomas principales son la inatención, hiperactividad e impulsividad. Por muchos años se pensó que afectaba solo a los niños; actualmente en el DSM 5 se acepta que se puede diagnosticar en adolescentes y adultos. El tratamiento debe ser individualizado, los objetivos principales son mejorar los síntomas centrales de las personas con TDAH, y su calidad de vida. El abordaje terapéutico es psicológico, conductual y farmacológico. Los medicamentos se clasifican en estimulantes y no estimulantes, siendo los de primera línea los estimu lantes tales como el metilfenidato, lisdexanfetamina y dexanfetamina. Entre los no estimulantes se cuentan a la guanfacina y atomoxetina. El tratamiento es funda mental porque mejora la calidad de vida de la persona a nivel familiar, educativo, laboral y social.

Abstract Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder of biological origin with a 70 to 80% genetic basis, which affects 5% of children and adolescents and 2.5% of adults, whose main symptoms are inattention, hyperactivity, and impulsivity. For many years it was thought that it only affected children; currently in the DSM 5 it is accepted that it can be diagnosed in adolescents and adults. Treatment must be individualized, the main objec tives are to improve the core symptoms of people with ADHD, and their quality of life. The therapeutic approach is psychological, behavioral, and pharmacological. Medications are classified as stimulants and non-stimulants, with stimulants such as methylphenidate, lisdexamfetamine, and dexamphetamine being the first line. Non-stimulants include guanfacine and atomox etine. Treatment is essential because it improves the qual ity of life of the person at the family, educational, work, and social levels.

Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas.

AIM: Although non-radiographic axial spondyloarthritis (EspAax-nr) is well understood within health institutions, being considered along with radiographic EspAax (EspAax-r) as part of the same disease spectrum, patient understanding is unknown. The aim is to describe the patient's knowledge of the EspAax-nr entity. METHODS: Atlas 2017, promoted by the Spanish Federation of Spondylarthritis Associations (CEADE), aims to comprehensively understand the reality of EspAax patients from a holistic approach. A cross-sectional on-line survey of unselected patients with self-reported EspAax diagnosis from Spain was conducted. Participants were asked to report their diagnosis. Socio-demographic, disease characteristics and patient-reported outcomes (PROs) were compared between those patients self-reporting as EspAax-nr and EspAax-r. RESULTS: 634 EspAax patients participated. Mean age 45.7±10.9 years, 50.9% female and 36.1% university-educated. 35 (5.2%) self-reported as EspAax-nr. Compared to EspAax-r patients, those with EspAax-nr were more frequently women (48.6% vs 91.4%, p<0.001), had longer diagnostic delay (10.1±8.9 vs 8.5±7.6 years), higher psychological distress (GHQ-12: 7.5±4.9 vs 5.6±4.4) and similar degree of disease activity (BASDAI: 5.7±2.1 vs 5.7±2.0), and unemployment rates (20.0% vs 21.6%). 20.0% of EspAax-nr received biologics vs 36.9% of EspAax-r, p=0.043. Visits to the rheumatologist in the past year were similar in both groups (3.8±4.5 vs 3.2±3.8), while GP visits were much higher within EspAax-nr (8.0±10.7 vs 4.9±13.3 p=0.003). CONCLUSION: For the first time, EspAax-nr characteristics and PROs have been analyzed from the patient's perspective. Both groups reported similar trends with the exception of EspAax-nr being more frequently women, younger, having longer diagnostic delay and lower use of biologic therapy.

Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas / Similitudes y diferencias entre espondiloartritis axial no radiográfica y radiográfica: perspectiva del paciente utilizando la versión española del Atlas

Aim: Although non-radiographic axial spondyloarthritis (EspAax-nr) is well understood within health institutions, being considered along with radiographic EspAax (EspAax-r) as part of the same disease spectrum, patient understanding is unknown. The aim is to describe the patient's knowledge of the EspAax-nr entity. Methods: Atlas 2017, promoted by the Spanish Federation of Spondylarthritis Associations (CEADE), aims to comprehensively understand the reality of EspAax patients from a holistic approach. A cross-sectional on-line survey of unselected patients with self-reported EspAax diagnosis from Spain was conducted. Participants were asked to report their diagnosis. Socio-demographic, disease characteristics and patient-reported outcomes (PROs) were compared between those patients self-reporting as EspAax-nr and EspAax-r. Results: 634 EspAax patients participated. Mean age 45.7±10.9 years, 50.9% female and 36.1% university-educated. 35 (5.2%) self-reported as EspAax-nr. Compared to EspAax-r patients, those with EspAax-nr were more frequently women (48.6% vs 91.4%, p<0.001), had longer diagnostic delay (10.1±8.9 vs 8.5±7.6 years), higher psychological distress (GHQ-12: 7.5±4.9 vs 5.6±4.4) and similar degree of disease activity (BASDAI: 5.7±2.1 vs 5.7±2.0), and unemployment rates (20.0% vs 21.6%). 20.0% of EspAax-nr received biologics vs 36.9% of EspAax-r, p=0.043. Visits to the rheumatologist in the past year were similar in both groups (3.8±4.5 vs 3.2±3.8), while GP visits were much higher within EspAax-nr (8.0±10.7 vs 4.9±13.3 p=0.003). Conclusion: For the first time, EspAax-nr characteristics and PROs have been analyzed from the patient's perspective. Both groups reported similar trends with the exception of EspAax-nr being more frequently women, younger, having longer diagnostic delay and lower use of biologic therapy.(AU)

Objetivo: Aunque se comprende bien la espondiloartritis axial no radiográfica (EspAax-nr) dentro de las instituciones sanitarias, se desconoce la comprensión del paciente cuando se considera conjuntamente con la espondiloartritis axial radiográfica (r-axSpA), como parte del mismo espectro de la enfermedad. El objetivo de este artículo es describir el conocimiento del paciente de la entidad EspAax-nr. Métodos: El objetivo de Atlas 2017, promovido por la Federación Española de Asociaciones de Espondiloartritis (CEADE), es comprender la realidad de los pacientes con espondiloartritis axial (EspAax) desde un enfoque holístico. Se realizó una encuesta transversal online a pacientes españoles no seleccionados, con diagnóstico autoreportado de axSpA. Se solicitó a los participantes que informaran su diagnóstico. Se compararon las características sociodemográficas y los resultados reportados por el paciente (RPO) entre los pacientes que autoreportaron EspAax-nr y EspAax-r. Resultados: Participaron 634 pacientes de EspAax, con edad media de 45,7 ± 10,9 años, siendo mujeres el 50,9%, y un 36,1% con formación universitaria. Treinta y cinco de ellas (5,2%) autoreportaron EspAax-nr. En comparación con los pacientes de EspAax-r, aquellos con EspAax-nr eran mujeres con mayor frecuencia (48,6 vs. 91,4%, p < 0,001), tenían mayor demora en el diagnóstico (10,1 ± 8,9 vs. 8,5 ± 7,6 años), y mayor grado de angustia psicológica (12-item general health questionnaire [GHQ-12]: 7,5 ± 4,9 vs. 5,6 ± 4,4) y grado similar de actividad de la enfermedad (bath ankylosing spondylitis disease activity index [BASDAI]: 5,7 ± 2,1 vs. 5,7 ± 2), y tasas de desempleo (20 vs. 21,6%). El 20% de los pacientes de EspAax-nr recibían terapia biológica vs. el 36,9% de pacientes de r-axSpA, p = 0,043. (AU)

Tratamiento simplificado para pacientes con Hepatitis C / Simplified treatment for hepatitis C patients

El nuevo tratamiento simplificado con antivirales orales para pacientes con Hepatitis C puede ser abordado desde la atención primaria, lo que facilita el acceso de la población afectada por esta infección crónica. En este artículo se repasan los aspectos claves del diagnóstico, el esquema de tratamiento simplificado y los candidatos a recibirlo. (AU)

The new simplified treatment with oral antivirals for hepatitis C patients can be approached at the primary care level, facilitating access for the population affected by this chronic infection. This article reviews the key aspects of the diagnosis, the simplified treatment scheme, and the eligible candidates for the treatment. (AU)

Tratamiento del trastorno depresivo en adolescentes: revisión bibliográfica / Treatment of depressive disorder in adolescents: literature review

El trastorno depresivo en adolescentes es un diagnóstico en aumento que se ha asociado con una alta incidencia de patologías psiquiátricas en la adultez, con repercusiones en los resultados educativos, vocacionales, relaciones interpersonales, salud y bienestar físico y mental. Por lo tanto, es crucial el diagnóstico temprano y el tratamiento adecuado. El objetivo de la presente revisión bibliográfica fue analizar las alternativas terapéuticas tanto farmacológicas como no farmacológicas disponibles. Se llevó a cabo una búsqueda en PubMed de artículos publicados en los últimos 5 años y en Google Scholar desde el 2018. Los resultados sugieren que la terapia cognitivo conductual sigue siendo la intervención de primera línea con mayor respaldo de evidencia. Sin embargo, se observa que actividades como la actividad física, intervenciones psicoeducativas, estimulación magnética transcraneal, musicoterapia, yoga, biorretroalimentación, terapia del bosque, terapia basada en el arte e intervenciones digitales también han demostrado alivio de los síntomas en medida heterogénea. En cuanto al tratamiento farmacológico, los antidepresivos son la terapia de primera línea, siendo la fluoxetina y el escitalopram los más respaldados por la evidencia. Esta revisión destaca el interés en investigar el uso de otros fármacos como la lamotrigina y la ketamina, aunque la evidencia es incipiente y se requieren más ensayos controlados aleatorizados para determinar su efectividad.

Depressive disorder in adolescents is a diagnosis that has been increasing and is associated with a high incidence of psychiatric pathologies in adulthood, impacting educational and vocational outcomes, interpersonal relationships, as well as physical and mental well-being. Early diagnosis and proper treatment are crucial in addressing these issues. The objective of this bibliographic review was to examine available pharmacological and non-pharmacological therapeutic alternatives. The review involved a search on PubMed for articles published in the last 5 years and on Google Scholar since 2018. The available evidence suggests that cognitive-behavioral therapy remains the first-line intervention with the most support. However, physical activity, psychoeducational interventions, transcranial magnetic stimulation, music therapy, yoga, biofeedback, forest therapy, art-based therapy, and digital interventions have shown varying degrees of symptom relief. In terms of pharmacological treatment, antidepressants, particularly fluoxetine and escitalopram, are considered the first-line therapy based on the strongest evidence. The review also highlights the interest in exploring the use of other drugs such as lamotrigine and ketamine. However, more randomized controlled trials are needed to establish their effectiveness conclusively.

Tratamiento del trastorno de déficit de atención con hiperactividad en población pediátrica: revisión bibliográfica / Treatment of attention deficit hyperactivity disorder in the pediatric population: literature review

El Trastorno por Déficit de Atención con Hiperactividad (TDAH) es un trastorno del comportamiento común en la infancia, caracterizado por la presencia de hiperactividad, impulsividad, problemas de atención y dificultades en las interacciones sociales. El objetivo de esta revisión bibliográfica fue identificar los tratamientos disponibles para el manejo del TDAH, tanto farmacológicos como no farmacológicos. La búsqueda se realizó en PubMed y Google Scholar, recopilando 285 artículos. Se excluyeron aquellos que no estaban en inglés o español, incluían población adulta o no se ajustaban al propósito de la revisión. Se seleccionaron 48 artículos y se incluyeron finalmente 30 para la lectura. Se concluye que la evidencia sugiere un enfoque combinado de tratamiento farmacológico y no farmacológico. Entre los tratamientos farmacológicos, los estimulantes como el metilfenidato siguen siendo la opción de primera línea. Además, hay estudios preliminares que respaldan la suplementación de hierro, vitamina D, zinc, omega 3, ginseng rojo y proteína de suero de leche. En cuanto a los tratamientos no farmacológicos, hay una amplia variedad de estrategias terapéuticas, como psicoeducación, entrenamiento en habilidades sociales, terapia de aceptación y compromiso, entrenamiento para padres, neurofeedback, aplicaciones de juegos móviles, actividad física, higiene del sueño, estimulación magnética transcraneal, acupuntura y terapia asistida por caballos. Aunque estos estudios son prometedores, muchos son incipientes, y se requiere más investigación en este campo.

Attention Deficit Hyperactivity Disorder (ADHD) is a common behavioral disorder in childhood, characterized by the presence of hyperactivity and impulsivity, attention problems, and difficulties in social interactions. The objective of this bibliographic review was to identify the available treatments for the non-pharmacological and pharmacological management of ADHD. A search was conducted in PubMed for articles published in the last 5 years and in Google Scholar since 2018, resulting in 285 collected articles. Articles not in English or Spanish, including adults in their population, or not fitting the purpose of this review were excluded. Out of 48 selected articles for reading, 30 were finally included. The available evidence suggests a combined approach of pharmacological and non-pharmacological treatment. Stimulants such as methylphenidate continue to be the first-line treatment among pharmacological measures. Incipient studies recommend the use of iron, vitamin D, zinc, omega 3, red ginseng, and whey protein supplementation. Non-pharmacological measures include a variety of therapeutic strategies, such as psychoeducation, training in social skills, acceptance and commitment therapy, training for parents, neurofeedback, mobile game applications, physical activity, sleep hygiene, transcranial magnetic stimulation, acupuncture, and horse-assisted therapy. While these studies show promise, most are still in the early stages, emphasizing the need for further research in this area.

Documento de expertos sobre el uso apropiado de los SYSADOA en situaciones clínicas controvertidas / Experts Document About an Adequate Utilization of SYSADOAs in Controversial Clinical Situations

Antecedentes y objetivo: Los SYSADOA (del inglés, symptomatic slow-acting drugs for osteoarthritis) orales son compuestos naturales que han demostrado ser útiles y seguros en el tratamiento de la artrosis (AO). Sin embargo, su uso en ciertas situaciones clínicas carece aún de evidencia científica y recomendaciones claras. El objetivo de este trabajo fue conocer la opinión de un grupo de expertos sobre el uso de los SYSADOA en el tratamiento de la AO en situaciones clínicas controvertidas. Materiales y métodos: Siguiendo el método del uso apropiado mediante la técnica Delphi, se valoraron 206 consultas concretas, estructuradas en 24 preguntas clínicas. Un panel de expertos, compuesto por un total de 15 especialistas, respondió a las dos rondas de consulta a través de una plataforma online. Los resultados se analizaron y debatieron en una reunión presencial con los coordinadores y el comité científico. Según el porcentaje de panelistas que coincidieron en los mismos, se clasificaron los resultados en términos de unanimidad, consenso, mayoría y discrepancia. Resultados: Se consensuaron los siguientes puntos: (1) el fenotipo del paciente condiciona el uso de los SYSADOA orales; (2) los SYSADOA orales se consideran adecuados en la AO primaria (rodilla, mano y cadera) y en algunos tipos de AO secundaria; no se consideran adecuados en AO erosiva de manos, hombro, columna y tobillo; (3) los SYSADOA orales pueden ser prescritos a pacientes con riesgo o enfermedad cardiovascular, enfermedad digestiva, hipertensión, dislipemia, enfermedad vascular periférica, diabetes tipo 2 y, a excepción de diacereína, en pacientes con reflujo esofágico. No se obtuvo acuerdo en la prescripción de los SYSADOA orales en pacientes con enfermedad hepática y renal.(AU)

Background and objective: SYSADOAs (symptomatic slow-acting drugs for osteoarthritis) are natural compounds that have been shown to be useful and safe in the treatment of osteoarthritis (OA). However, their use in certain clinical situations still lacks scientific evidence and clear recommendations. The objective of this work was to learn the opinion of a group of experts regarding the appropriate use of SYSADOA in the treatment of OA in controversial clinical situations. Materials and methods: Following the Delphi technique, 206 specific consultations, structured in 24 clinical questions, were evaluated. A panel of experts composed of a total of 15 specialists, answered the two rounds of consultation through an online platform. The results were analysed and discussed in a face-to-face meeting with the coordinators and the scientific committee. According to the percentage of panellists who agreed on their findings, the results were classified in terms of unanimity, consensus, majority and discrepancy. Results: The following points were agreed upon: (1) the patient's phenotype determines the use of SYSADOAs; (2) SYSADOAs are considered appropriate in primary OA (knee, hand and hip) and in some types of secondary OA; they are not considered appropriate in OA of the shoulder, spine, ankle and erosive OA of the hands; (3) SYSADOAs may be prescribed for patients at risk of or with cardiovascular disease, digestive disease, hypertension, dyslipaemia, peripheral vascular disease, type 2 diabetes and, excluding diacerein, for patients with oesophageal reflux. No agreement was obtained on the prescription of SYSADOAs for patients with hepatic and renal disease. Conclusions: There is limited literature on the use of SYSADOAs for the treatment of OA in controversial situations. Through this work it has been possible to establish the position of a group of experts regarding clinical situations for which there is no scientific evidence concerning their use.(AU)

Experts document about an adequate utilization of SYSADOAs in controversial clinical situations.

BACKGROUND AND OBJECTIVE: SYSADOAs (Symptomatic Slow-Acting Drugs for Osteoarthritis) are natural compounds that have been shown to be useful and safe in the treatment of osteoarthritis (OA). However, their use in certain clinical situations still lacks scientific evidence and clear recommendations. The objective of this work was to learn the opinion of a group of experts regarding the appropriate use of SYSADOA in the treatment of OA in controversial clinical situations. MATERIALS AND METHODS: Following the Delphi technique, 206 specific consultations, structured in 24 clinical questions, were evaluated. A panel of experts composed of a total of 15 specialists, answered the two rounds of consultation through an online platform. The results were analysed and discussed in a face-to-face meeting with the coordinators and the scientific committee. According to the percentage of panellists who agreed on their findings, the results were classified in terms of unanimity, consensus, majority and discrepancy. RESULTS: The following points were agreed upon: (1) the patient's phenotype determines the use of SYSADOAs; (2) SYSADOAs are considered appropriate in primary OA (knee, hand and hip) and in some types of secondary OA; they are not considered appropriate in OA of the shoulder, spine, ankle and erosive OA of the hands; (3) SYSADOAs may be prescribed for patients at risk of or with cardiovascular disease, digestive disease, hypertension, dyslipaemia, peripheral vascular disease, type 2 diabetes and, excluding Diacerein, for patients with oesophageal reflux. No agreement was obtained on the prescription of SYSADOAs for patients with hepatic and renal disease. CONCLUSIONS: There is limited literature on the use of SYSADOAs for the treatment of OA in controversial situations. Through this work it has been possible to establish the position of a group of experts regarding clinical situations for which there is no scientific evidence concerning their use. This work may contribute towards improving the management protocols of SYSADOAs in the treatment of OA and offer a useful approach in uncertain situations.

Prevalencia de acontecimientos adversospor medicamentos en los servicios de urgencias. Proyecto multicéntrico FARM-URG / Prevalence of adverse drug events in emergency departments. FARM-URG multi-center project

Objetivo: Los acontecimientos adversos por medicamentos son una causaconocida de asistencia a los servicios de urgencias. El objetivo del proyectoFARM-URG, impulsado por el Grupo de Trabajo REDFASTER de la SociedadEspañola de Farmacia Hospitalaria, es evaluar estos acontecimientos adversos mediante cortes periódicos. En este estudio se muestran los resultadosdel primer registro. Sus objetivos fueron determinar la prevalencia de acontecimientos adversos respecto al total de pacientes atendidos y caracterizarlos.Método: Estudio multicéntrico transversal realizado en los servicios deurgencias de hospitales españoles. La identificación y registro de pacientesse obtuvo a partir del censo de pacientes atendidos en urgencias en elmomento del corte (16 de junio de 2020). Se revisaron las historias clínicasretrospectivamente y se registraron los datos en la plataforma REDCap®.Resultados: En este corte FARM-URG de 2020 participaron 13 hospitales, que evaluaron 772 pacientes, de los cuales 57 (7,4%) habían consultadopor un acontecimiento adverso por medicamentos. El grupo de fármacosantitrombóticos fue responsable de la mayor parte de estos episodios, siendoacenocumarol (22,8%) el principal fármaco implicado. (AU)

Objective: Adverse drug events are a well-known cause of emergency department admissions. FARM-URG is a project promoted by theREDFASTER working group of the Spanish Society of Hospital Pharmacy.Its aim is to evaluate these adverse events through regular prevalencemeasurements. The present study shows the results of the first observations.The goal was to determine the prevalence of adverse drug events withrespect to the total number of patients treated in emergency departmentsand carry out a description of the different events identified.Method: This is a multicenter cross-sectional study carried out in theemergency room of 13 Spanish hospitals. The identification and registration of patients were obtained from the emergency department patientcensus at the time of the first prevalence measurement (16 June 2020). TheREDCap® platform was used for patient registration.Results: The 2020 FARM-URG registry, which included 13 hospitals,evaluated 772 patients, of whom 57 (7.4%) consulted for adverse drugevents. Antithrombotic drugs were responsible for most of these episodes, acenocoumarol being the main drug involved (22.8%). (AU)

Arsenal farmacológico en artropatías de origen enteropático / Pharmacological arsenal in arthropathies with enteropathic origin

Introducción: Más de la mitad de los pacientes con Enfermedad Inflamatoria Intestinal (EII) presenta al menos una manifestación extraintestinal, principal-mente articular, con interferencias en la calidad de vida. Además, los mecanismos patogénicos que explican el vínculo entre las patologías intestinal y la articular aún no están bien definidos. El objetivo del presente trabajo es revisar el arsenal farmaco-terapéutico actual frente a artropatías asociadas a EII.Método: Se realizó una búsqueda bibliográfica de la literatura, las bases de datos consultadas fueron Medline a través de PubMed y Scopus desde el 14 hasta el 22 de diciembre. Se seleccionaron estudios realizados en los últimos 15 años. Las palabras clave empleadas fueron: Spondyloarthritis, “inflammatory bowel disease” and “pharmacologic therapy”. También se consultó la European Crohn's and Colitis Organisation (ECCO) y la European Me-dicines Agency (EMA).Resultados: Existen diferencias entre el abordaje terapéutico de las espondiloartritis axial y periféri-ca. El manejo farmacológico ha consistido princi-palmente en aminosalicilatos, corticoides, inmu-nosupresores, metotrexato y agentes biológicos entre los que destaca el infliximab por su acción dual sobre las afecciones intestinales y articulares. Recientemente han surgido terapias mejor dirigi-das, en busca de tratamientos más personalizados como el vedolizumab, ustekinumab e inhibidores selectivos de la tirosina quinasas asociadas a JANUS (JAK).Conclusión: Los protocolos son muy dispares entre las fuentes consultadas, lo que pone de manifiesto la necesidad de un manejo de las patologías de manera integral multidisciplinar que mejoraría la calidad de vida del paciente. Consensuar el abor-daje óptimo para cada caso se presenta como un desafío tanto para el gastroenterólogo como para el reumatólogo.(AU)

Introduction: More than half of the patients with Inflammatory Bowel Disease (IBD) present, at least, one extraintestinal manifestation, mainly articular, with interference in their quality of life. Furthermore, the pathogenic mechanisms that explain the link between intestinal and joint pathologies are not well defined yet. The aim of this work is to review the current pharmacotherapeutical arsenal against arthropathies associated with IBD.Method: A bibliographic search of the literature was undertaken, the databases consulted were Medline through PubMed and Scopus from December 14 to 22. Only studies carried out in the last 15 years were selected. The keywords used were: Spon-dyloarthritis, “inflammatory bowel disease” and “pharmacologic therapy”. The European Crohn's and Colitis Organization (ECCO) and the European Medicines Agency (EMA) were also consulted.Results: There are differences between the ther-apeutic approach to axial and peripheral spon-dyloarthritis. Pharmacological management has included mainly of aminosalicylates, corticoste-roids, immunosuppressants, methotrexate and biological agents, among which infliximab stands out due to its dual action on intestinal and joint conditions. Better targeted therapies such as vedolizumab, ustekinumab, and selective inhibitors of JANUS-associated tyrosine kinases (JAK) have recently emerged in search of more personalized treatments.Conclusion: The algorithms are very disparate among the consulted sources, which highlights the need for a comprehensive multidisciplinary management that would improve the quality of life of the patient. Reaching consensus on the optimal approach for each case is a challenge for both the gastroenterologist and the rheumatologist.(AU)

Uso de la ivrabadina para el tratamiento de la taquicardia ectópica de la unión congénita / Use of ivabradine for the treatment of congenital junctional ectopic tachycardia

Resumen La taquicardia ectópica de la unión en su variante congénita es una taquiarritmia pediátrica poco frecuente, que por su naturaleza incesante y su refractariedad a los agentes farmacológicos tradicio nales lleva asociada una alta morbimortalidad. Se presentan los casos clínicos de dos pacientes pediátricos con diagnóstico de taquicardia ectópica de la unión congénita, que mostraron respuesta inadecuada a las alternativas de tratamiento habituales y que, en consecuencia, desarrollaron miocardiopatía dilatada y disfunción ventricular secundaria a la taquicardia sostenida. En ambos se utilizó ivabradina como alternativa farmacológica innovadora pare el control de ésta con excelente respuesta clínica.

Abstract The congenial form of junctional ectopic tachycardia is a rare variant of pediatric tachyarrhythmia that due to its incessant nature and its refractoriness to the traditionally used antiarrhythmic agents has a high morbimortality The clinical cases of two patients with a diagnosis of congenital junctional ectopic tachycardia with inadequate response to the regular pharmacological options, who developed dilated cardiomyopathy and ventricular dysfunc tion secondary to sustained tachycardia, are presented. In both ivrabadine, a new innovative option was used with excellent clinical response.

Desequilibrio electrolítico por medicamentos y sustancias tóxicas / Electrolyte imbalance related to drugs and toxic substances

Las alteraciones del equilibrio hidroelectrolítico pueden ser primarias o secundarias al proceso mismo de una enfermedad, a la terapia farmacológica, o en algunos casos a la exposición intencional o no a sustancias tóxicas. El diagnóstico de los trastornos electrolíticos se establece por medio del análisis de laboratorio clínico, pero su interpretación debe ser correlacionada con el contexto clínico del paciente. Los medicamentos pueden interferir con la absorción de los electrolitos, alterar las respuestas hormonales que afectan la homeostasis, o bien impactar de forma directa la función del órgano responsable de mantener el balance electrolítico [1-2]. Entender los mecanismos fisiopatológicos de estas potenciales anormalidades, permite al clínico anticipar, vigilar y corregir de forma temprana, evitando alteraciones graves en el paciente

Relación entre las concentraciones séricas devedolizumab en fase de inducción y respuesta temprana y mantenida en el primer año de tratamiento en pacientes con colitis ulcerosa / Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis

Objetivo: La evidencia sobre la utilidad de la monitorización proactiva delas concentraciones séricas de vedolizumab en la fase de inducción del tratamiento es limitada. El objetivo del estudio ha sido evaluar la capacidad delas concentraciones séricas de vedolizumab determinadas en esta fase parapredecir la respuesta al tratamiento en pacientes con colitis ulcerosa, con el finde establecer si los pacientes se beneficiarían clínicamente de una monitorización precoz.Método: Estudio descriptivo, prospectivo, realizado en tres hospitalesgenerales públicos. Incluyó a los pacientes adultos con colitis ulcerosa, queiniciaron tratamiento con vedolizumab en los centros participantes desdejunio de 2019 a junio de 2020. Se determinaron las concentraciones séricas de vedolizumab en las semanas 6 y 14 de tratamiento. La respuestabioquímica, clínica y endoscópica se evaluó en las semanas 6, 14 y 52.Se estudió la relación de las concentraciones séricas de vedolizumab determinadas en la semana 6 con la respuesta temprana al tratamiento, asícomo la relación de las concentraciones séricas de vedolizumab en lassemanas 6 y 14 con la persistencia de respuesta al año de tratamiento. (AU)

Objective: Evidence on the usefulness of proactive monitoring of vedolizumab serum concentrations during the induction phase of treatment islimited. The objective of our study was to evaluate the effectiveness ofmeasuring such concentrations during this phase in predicting responseto treatment in patients with ulcerative colitis with a view to determiningwhether patients would benefit from early monitoring of vedolizumabserum concentrations.Method: This was a prospective descriptive study carried out at threepublic general hospitals. It included adult patients with ulcerative colitiswho were initiated on vedolizumab at the participating hospitals from June2019 to June 2020. Vedolizumab serum concentrations were determined at weeks 6 and 14. Response to treatment was biologically, clinically,and endoscopically evaluated at weeks 6, 14, and 52. An analysis wasmade of the relationship between vedolizumab serum concentrations atweek 6 and early response to treatment, and of the relationship betweenthe vedolizumab serum concentrations at weeks 6 and 14 and persistentresponse at one year. (AU)

Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas.

AIM: Although non-radiographic axial spondyloarthritis (EspAax-nr) is well understood within health institutions, being considered along with radiographic EspAax (EspAax-r) as part of the same disease spectrum, patient understanding is unknown. The aim is to describe the patient's knowledge of the EspAax-nr entity. METHODS: Atlas 2017, promoted by the Spanish Federation of Spondylarthritis Associations (CEADE), aims to comprehensively understand the reality of EspAax patients from a holistic approach. A cross-sectional on-line survey of unselected patients with self-reported EspAax diagnosis from Spain was conducted. Participants were asked to report their diagnosis. Socio-demographic, disease characteristics and patient-reported outcomes (PROs) were compared between those patients self-reporting as EspAax-nr and EspAax-r. RESULTS: 634 EspAax patients participated. Mean age 45.7±10.9 years, 50.9% female and 36.1% university-educated. 35 (5.2%) self-reported as EspAax-nr. Compared to EspAax-r patients, those with EspAax-nr were more frequently women (48.6% vs 91.4%, p<0.001), had longer diagnostic delay (10.1±8.9 vs 8.5±7.6 years), higher psychological distress (GHQ-12: 7.5±4.9 vs 5.6±4.4) and similar degree of disease activity (BASDAI: 5.7±2.1 vs 5.7±2.0), and unemployment rates (20.0% vs 21.6%). 20.0% of EspAax-nr received biologics vs 36.9% of EspAax-r, p=0.043. Visits to the rheumatologist in the past year were similar in both groups (3.8±4.5 vs 3.2±3.8), while GP visits were much higher within EspAax-nr (8.0±10.7 vs 4.9±13.3 p=0.003). CONCLUSION: For the first time, EspAax-nr characteristics and PROs have been analyzed from the patient's perspective. Both groups reported similar trends with the exception of EspAax-nr being more frequently women, younger, having longer diagnostic delay and lower use of biologic therapy.

Dolor lumbar: revisión y evidencia de tratamiento / Low back pain: review and evidence of treatment

El dolor lumbar corresponde a uno de los síntomas más prevalentes en la humanidad, siendo la segunda causa más frecuente de atención médica a nivel mundial. Existen diversos enfoques de diagnóstico y tratamiento para dolor lumbar, entre ellos la temporalidad del síntoma, el trabajo de diagnóstico sindromático, los síntomas de alarma, también llamados "banderas rojas", que pueden hacer sospechar patologías de mayor gravedad o urgencia. El estudio etiológico puede ser necesario en casos agudos con estas banderas rojas y en casos crónicos. Este estudio se realiza principalmente con imágenes (radiografías, tomografía computada, resonancia magnética, SPECT/CT) y ocasionalmente con exámenes de laboratorio. La mayor parte de los tratamientos están enfocados en el manejo conservador, principalmente el ejercicio físico guiado y asociado a fármacos analgésicos. Existen terapias alternativas tales como la acupuntura, el tai-chi, entre otros, algunas de ellas han mostrado ser un buen complemento al manejo del dolor lumbar. El enfoque multidisciplinario es la tendencia más actual de manejo, esto incluye el trabajo e intervención de diversos profesionales abordando el problema de forma integral, incluyendo el manejo psicoterapéutico. Intervenciones como las infiltraciones de columna han demostrado reducir el dolor por tiempos cortos, siendo útiles como puente para realizar un tratamiento apropiado. La cirugía solo se reserva para casos refractarios, siendo controversiales los resultados existentes en la literatura.

Low back pain is one of the most prevalent symptoms in humanity, being the second most common cause of medical attention worldwide. There are various approaches to diagnosis and treatment for low back pain, including the temporality of the symptom, the work of syndromatic diagnosis, the alarm symptoms, also called "red flags", that can make suspect pathologies of greater severity or emergency. The etiological study may be necessary in acute cases with these "red flags" and in chronic cases. This study is mainly done with images (X-rays, CT scan, MRI, SPECT/CT) and occasionally with laboratory tests. Most of the treatments are focused on conservative management, mainly guided physical exercise associated with analgesic drugs. There are alternative therapies such as acupuncture, tai-chi, among others, some of them have proven to be a good complement to the management of low back pain. The multidisciplinary approach is the most current management trend, this includes the work and intervention of various professionals addressing the problem in an integral way, including psychotherapeutic management. Interventions such as spinal infiltrations have been shown to reduce pain for short times, being useful as a bridge for proper treatment. Surgery is only reserved for refractory cases, the results existing in the literature being controversial.

Experts Document About an Adequate Utilization of SYSADOAs in Controversial Clinical Situations. / Documento de expertos sobre el uso apropiado de los SYSADOA en situaciones clínicas controvertidas.

BACKGROUND AND OBJECTIVE: SYSADOAs (symptomatic slow-acting drugs for osteoarthritis) are natural compounds that have been shown to be useful and safe in the treatment of osteoarthritis (OA). However, their use in certain clinical situations still lacks scientific evidence and clear recommendations. The objective of this work was to learn the opinion of a group of experts regarding the appropriate use of SYSADOA in the treatment of OA in controversial clinical situations. MATERIALS AND METHODS: Following the Delphi technique, 206 specific consultations, structured in 24 clinical questions, were evaluated. A panel of experts composed of a total of 15 specialists, answered the two rounds of consultation through an online platform. The results were analysed and discussed in a face-to-face meeting with the coordinators and the scientific committee. According to the percentage of panellists who agreed on their findings, the results were classified in terms of unanimity, consensus, majority and discrepancy. RESULTS: The following points were agreed upon: (1) the patient's phenotype determines the use of SYSADOAs; (2) SYSADOAs are considered appropriate in primary OA (knee, hand and hip) and in some types of secondary OA; they are not considered appropriate in OA of the shoulder, spine, ankle and erosive OA of the hands; (3) SYSADOAs may be prescribed for patients at risk of or with cardiovascular disease, digestive disease, hypertension, dyslipaemia, peripheral vascular disease, type 2 diabetes and, excluding diacerein, for patients with oesophageal reflux. No agreement was obtained on the prescription of SYSADOAs for patients with hepatic and renal disease. CONCLUSIONS: There is limited literature on the use of SYSADOAs for the treatment of OA in controversial situations. Through this work it has been possible to establish the position of a group of experts regarding clinical situations for which there is no scientific evidence concerning their use. This work may contribute towards improving the management protocols of SYSADOAs in the treatment of OA and offer a useful approach in uncertain situations.

Tratamiento farmacológico y génico en las distrofias musculares de Duchenne y Becker / Pharmacologic and genetic treatment in the Duchenne and Becker muscular dystrophies

Introducción: Las distrofias musculares son las enfermedades degenerativas más comunes dentro de las enfermedades neuromusculares, cursan con debilidad muscular que progresa hasta la pérdida de la deambulación y en la segunda década de vida surgen complicaciones cardíacas, respiratorias y ortopédicas. Objetivo: Analizar el estado actual de los tratamientos génico y farmacológico en las distrofias musculares de Duchenne y Becker Métodos: Se realizó una búsqueda en los meses de enero, febrero y marzo de 2018 en las bases de datos Medline, Cinhal, Web Of Science y Scopus. Se obtuvieron 232 resultados y después de aplicar los criterios de inclusión y exclusión, se consiguieron para analizar 15 artículos válidos para la revisión. Resultados: Los artículos analizados investigan mayoritariamente el efecto de las terapias mencionadas a nivel de funcionalidad y de síntesis de la proteína distrofina durante períodos largos, en los que participan muestras de tamaño y edades variadas tanto como distrofia muscular de Duchenne y como distrofia muscular de Becker. Conclusiones: Existen más artículos enfocados en la distrofia muscular de Duchenne que en la distrofia muscular de Becker. Esto puede ser debido a que la primera es la más grave y de peor pronóstico. Sigue siendo necesario realizar más estudios para avanzar sobre el estado actual de estos tratamientos(AU)

Introduction: Muscular dystrophies are one of the most common degenerative pathologies within neuromuscular diseases. They present muscular weakness that develops until loss of wandering and in the second decade of life can appear cardiac, respiratory and orthopaedic complications. Objective: To know the current state of genetic and pharmacology treatments in the Duchenne and Becker muscular dystrophies. Methods: A search was made from January to March 2018 at Medline, Cinhal, Web Of Science and Scopus databases. 232 results were obtained, and applying the inclusion and exclusion criteria, 15 acceptable articles for reviewing were found. Results: Analyzed articles mostly investigate the effect of the mentioned therapies in the levels of functionality and dystrophin protein synthesis during long periods, in which samples of different sizes and ages are used. Conclusions: There are more articles focused on Duchenne Muscular Dystrophy than Becker Muscular Dystrophy. That can be due to the fact that the first is the most severe and with the worst prognosis. It is still necessary to carry out more scientific studies to move forward from the current stage of these treatments(AU)

Fatores associados ao uso de medicamentos potencialmente inapropriados em idosos urbanos e rurais / Factors associated with the use of medicines potentially inadequate for urban and rural elderly people

Este estudo objetivou verificar a associação entre uso de medicamentos potencialmente inapropriados e zona de moradia, condições de saúde, hábitos de vida e capacidade funcional de idosos urbanos e rurais. Trata-se de um estudo transversal, recorte de um estudo de base populacional sobre condições de vida e saúde de idosos residentes nas zonas urbana e rural do município de Estação (RS). Por meio de inquérito domiciliar, os 313 idosos entrevistados autorreferiram informações pessoais e familiares, condições de saúde e hábitos de vida e avaliação funcional. As informações coletadas foram codificadas e armazenadas em um banco de dados. Os dados foram analisados e as medicações utilizadas e sua classificação quanto aos Critérios de Beers, versão 2012 foram identificadas. O estudo evidenciou uma prevalência elevada quanto ao uso de medicamentos potencialmente inapropriados em idosos. As classes terapêuticas de medicamentos mais utilizadas foram drogas antiarrítmicas, benzodiazepínicos e anti-inflamatórios não esteroidais. Identificou-se associação positiva entre o uso de medicamentos potencialmente inapropriados e dor, quedas, atividade física, diabetes, problemas no sono, nervosismo, problemas cardíacos, depressão e atividades básicas da vida diária. Tal evidência reforça a necessidade de capacitação e sensibilização dos profissionais de saúde para a avaliação da terapia medicamentosa.

The association between the use of potentially inadequate medicines and living sites, health conditions, habits and functional capacity of urban and rural elderly people is analyzed. Current transversal study is a section of a population-based investigation on health and life conditions of elderly people living in the urban and rural zones of the municipality of Estação RS Brazil. A home survey was conducted with 313 elderly people who provided their personal and family data, health conditions, habits and functional evaluation. Information was codified and stored in a data base. Data on medicines used and their classification were analyzed according to Beer´s Criteria v. 2012. Investigation revealed high prevalence of medicine which was potentially inadequate for the elderly. Antiarrhythmic, benzodiazepines and non -steroid anti-inflammatory drugs were the most employed drug therapeutic classes. A positive association between the use of potentially inadequate medicines and pain, falls, physical activity, diabetes, insomnia, nervousness, heart condition, depression and daily basic activities was identified. Results reinforce the need for capacitation and sensitiveness of health professionals to assess medicinal therapy.

Polypharmacy and enteral nutrition in patients with complex chronic diseases / La polifarmacia del paciente crónico complejo y la nutrición enteral.

Oral medications are often administered through enteral feeding tubes in patients with complex chronic diseases. It is important to consider possible interactions between drugs and enteral nutrition that might lead to unsuccessful treatment or tube occlusion. These patients become subjects for higher risk of problems and errors such as drug incompatibility with enteral nutrition and inappropriate dosage form selection. It is possible to minimize the risk of tube occlusion and incompatibilities problems by recognizing potential medication errors, selecting the most appropriate drug and dosage form and using appropriate administration techniques. In this context, high-alert medications for patients with chronic diseases deserve special attention. Furthermore, risk exposure should be considered among healthcare professionals and patient caregivers handling hazardous drugs. Therefore, main incompatibility problems between drugs and enteral nutrition have been reviewed, including general recommendations for administration of oral medications through enteral feeding tubes and safe handling of hazardous drugs. Specific recommendations for administration of high-alert medications for patients with chronic diseases are also included.